Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Postmenopausal women who have attended the 20030216 (NCT00089791) study month 36 visit will be eligible to participate if they meet the inclusion and exclusion criteria given below.~Inclusion Criteria~* Subjects must sign the informed consent before any study specific procedures are performed and agree to receive denosumab 60 mg subcutaneous injection every 6 months~* Subjects must not have discontinued investigational product during the 20030216 study and must have attended the 20030216 study month 36 visit~* Subjects must be re-consented prior to (or at) the 24 month visit for participation beyond month 24.~Exclusion Criteria~* Permanently non-ambulatory subjects (use of an assistive device eg, cane, walker, etc. is permitted)~* Missed 2 or more investigational product doses during the 20030216 study~* Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures~* Developed sensitivity to mammalian cell derived drug products during the 20030216 study~* Unable to tolerate calcium supplementation during the last 6 months of participation in the 20030216 study (between the month 30 and month 36 20030216 study visits)~* Currently receiving any investigational product other than denosumab or having received any investigational product during the 20030216 study~* Current use of the following osteoporosis agents: bisphosphonates, calcitonin, fluoride, parathyroid hormone, selective estrogen receptor modulators, systemic oral or transdermal estrogen (except vaginal preparations and estrogen creams which are acceptable), strontium, or tibolone~* For bone biopsy sub-study subjects only: known or suspected sensitivity or contraindication to tetracycline derivatives

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 94 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.

Based on this trial design, predict the completion outcome and termination type (if applicable).